Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-001 in healthy volunteers
NCT06363383Phase 1Completed
- Sponsor
- Mage Biologics Inc.
- Start
- May 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing MB-001 capsules with Placebo capsules (2 arms). Primary endpoints: Adverse Events at 33 days, Vital Signs at 33 days and 3 more. Started May 2024; status: completed.
02
Drugs
MB-001
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06363383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06363383.